PDCD1 and non-small cell lung carcinoma: First-line pembrolizumab, an immune checkpoint inhibitor that targets PD-1, in combination with pemetrexed-carboplatin continues to demonstrate increased response and survival in advanced NSCLC in comparison to chemotherapy alone [38, 39].